Pulmonary Immune Cell-microbiome Interactions in the Healthy Lung

ConditionHealthy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-75
SponsorHvidovre University Hospital

About this trial

The overall aim is to to provide a normal material for the composition and spatial heterogeneity of the following in the healthy lung: i) immune cell populations and their activation patterns, ii) the surrounding cytokine-chemokine milieu, including trans-compartmental fluxes of these mediators between the lung and bloodstream, and iii) the lung microbiome.

Main hypotheses:

* Absolute and relative immune cell counts in bronchoalveolar lavage fluid (BALF) are similar to those previously reported by other methods6,7. * No trans-compartmental flux of cytokines between the lungs and bloodstream is present, but cytokine concentrations (notably IL-6 and IL-8) vary with the immune-cell-microbiome composition. * Immune cell (mainly T cell) activation, differentiation, and gene expression patterns are expected to differ between blood and BALF in a manner that depends on the regional diversity of the pulmonary microbiome.

Eligibility criteria

Qualifiers

Men and women

Age 40 to 75

Disqualifiers

Immune deficiency

Lung disease

Active cancer or infection

Absolute contraindications for bronchoscopy

Trial design

Treatments tested in this trial

  • Bronchoalveolar lavage

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators